Suchergebnisse - "Shah, Rashmi R"

PubPharm (10)

1

Safety and Tolerability of Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitors in Oncology

enthalten in: Drug safety | 2019

von Shah, R. | Shah, D.

2

Anti-Angiogenic Tyrosine Kinase Inhibitors and Reversible Posterior Leukoencephalopathy Syndrome : Could Hypomagnesaemia Be the Trigger?

enthalten in: Drug safety | 2017

von Shah, R.

3

Hyperglycaemia Induced by Novel Anticancer Agents : An Undesirable Complication or a Potential Therapeutic Opportunity?

enthalten in: Drug safety | 2017

von Shah, R.

4

Tyrosine Kinase Inhibitor-Induced Interstitial Lung Disease : Clinical Features, Diagnostic Challenges, and Therapeutic Dilemmas

enthalten in: Drug safety | 2016

von Shah, R.

5

Update on Cardiovascular Safety of Tyrosine Kinase Inhibitors : With a Special Focus on QT Interval, Left Ventricular Dysfunction and Overall Risk/Benefit

enthalten in: Drug safety | 2015

von Shah, R. | Morganroth, J.

6

Effect of tyrosine kinase inhibitors on wound healing and tissue repair : implications for surgery in cancer patients

enthalten in: Drug safety | 2014

von Shah, D. | Dholakia, S. | Shah, R.

7

A fresh perspective on comparing the FDA and the CHMP/EMA : approval of antineoplastic tyrosine kinase inhibitors

enthalten in: British journal of clinical pharmacology | 2013

von Shah, R. | Roberts, S. | Shah, D.

8

Hepatotoxicity of tyrosine kinase inhibitors : clinical and regulatory perspectives

enthalten in: Drug safety | 2013

von Shah, R. | Morganroth, J. | Shah, D.

9

Tyrosine kinase inhibitors : their on-target toxicities as potential indicators of efficacy

enthalten in: Drug safety | 2013

von Shah, D. | Shah, R. | Morganroth, J.

10

Cardiovascular safety of tyrosine kinase inhibitors : with a special focus on cardiac repolarisation (QT interval)

enthalten in: Drug safety | 2013

von Shah, R. | Morganroth, J. | Shah, D.

1
[1]